Hong Kong Stock Movement | YIDU TECH (02158) Surges Over 14% as AI Expected to Empower Clinical Trials, Subsidiary Wins Bid for SMR001 Eye Drops Phase III Clinical Research Project

Stock News
昨天

YIDU TECH (02158) surged over 14% in late trading, and as of press time, the stock was up 12.89% to HK$6.57 with a trading volume of HK$466 million. On the news front, YIDU TECH recently announced that its affiliated company Tianjin Happy Life Technology Co., Ltd. has won the bid for Shandong Yandu Biotechnology Co., Ltd.'s recombinant human nerve growth factor (SMR001) eye drops Phase III clinical research project, with a total project value of approximately RMB 55.82 million. Notably, on September 16, the 2025 Tencent Digital Ecosystem Conference Medical Special Session was held. YIDU TECH's senior solution expert Shi Cheng delivered a keynote speech on "AI Empowering the Full Process of Clinical Trials," combining YIDU TECH's years of technological accumulation and practical cases to comprehensively explain the pathways through which AI can effectively improve the efficiency and quality of clinical trials from technical support and scenario implementation to ecosystem construction, driving high-quality industry development.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10